Cargando…
Optimal timing of combining sorafenib with trans-arterial chemoembolization in patients with hepatocellular carcinoma: A meta-analysis
BACKGROUND: The combination therapy of trans-arterial chemoembolization (TACE) and sorafenib were proved to be one of the effective methods for intermediate and advanced hepatocellular carcinoma (HCC). Although it has been confirmed that the combination therapy can prolong survival for advanced HCC...
Autores principales: | Dai, Yanmei, Jiang, Huijie, Jiang, Hao, Zhao, Sheng, Zeng, Xu, Sun, Ran, Zheng, Ruoshui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Neoplasia Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8515486/ https://www.ncbi.nlm.nih.gov/pubmed/34628285 http://dx.doi.org/10.1016/j.tranon.2021.101238 |
Ejemplares similares
-
Optimizing outcomes in HCC: Comment on “optimal timing of combining sorafenib with trans-arterial chemoembolization in patients with hepatocellular carcinoma: A meta-analysis” by Jiang et al.
por: Rizzo, Alessandro
Publicado: (2021) -
Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A systematic review and meta-analysis
por: Liu, Jun-Ning, et al.
Publicado: (2023) -
Corrigendum: Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis
por: Liu, Jun-Ning, et al.
Publicado: (2023) -
Trans-catheter arterial chemoembolization plus Sorafenib, an unsuccessful therapy in the treatment of hepatocellular carcinoma?: A systematic review and meta-analysis
por: Zhang, Tao, et al.
Publicado: (2020) -
Transarterial chemoembolization combined with sorafenib for advanced hepatocellular carcinoma
por: SHAO, WENBO, et al.
Publicado: (2014)